FDA's Gottlieb Applauds Drug Rebates At Point-Of-Sale
Executive Summary
The US FDA commissioner called recent initiatives to get drug rebates to patients at point-of-sale "healthy" public policy, and suggested insurance premiums have been subsidized by sick patients, addressing CNBC's health care conference.
You may also be interested in...
Gottlieb Unleashed: Focus on Drug Pricing To Intensify As He Rejoins AEI
Without constraints of being FDA commissioner, Gottlieb will have podium to push for changes to drug pricing and competition.
A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?
US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.
Will Biosimilars Lead To Better Biologics Manufacturing?
US FDA Commissioner Gottlieb is promising new policies to improve biologics manufacturing as part of agency’s action plan to accelerate biosimilar development. That follows the pattern set 25 years ago with generic drugs and brand manufacturing.